A study using multimodal imaging to understand liver cancer and how patients respond to treatment

Multimodal clinical magnetic resonance elastography and ex-vivo multiscale imaging to define biomechanical and molecular determinants of treatment response in hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10326992

Enrollment

Registered

2026-06-10

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable/metastatic hepatocellular carcinoma (HCC) Cancer

Interventions

This is a prospective longitudinal observational cohort study involving 40 adults with advanced hepatocellular carcinoma (HCC) receiving standard-of-care immunotherapy. The study aims to understand ho

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years 2. Radiologically or histologically confirmed HCC 3. Planned initiation of atezolizumab-bevacizumab 4. At least one measurable lesion suitable for biopsy 5. Child-Pugh A or stable B7 6. Able to undergo MRI/MRE

Exclusion criteria

Exclusion criteria: 1. Contraindications to MRI 2. Severe coagulopathy precluding biopsy 3. Prior liver transplant 4. Active uncontrolled infection 5. Eastern Cooperative Oncology Group (ECOG) >2 6. Pregnancy or lactation

Countries

Virgin Islands, British

Contacts

Public ContactMzamo Mbelle

mzamo.mbelle@nhs.net+44 (0)20 7848 5332

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 29, 2026